keyword
MENU ▼
Read by QxMD icon Read
search

Graves orbitopathy

keyword
https://www.readbyqxmd.com/read/28548552/serum-cyr61-is-associated-with-disease-activity-in-graves-orbitopathy
#1
Young Jun Woo, Yuri Seo, Jin Joo Kim, Ji Won Kim, Yil Park, Jin Sook Yoon
PURPOSE: To investigate the clinical implications of cysteine-rich angiogenic inducer 61 (CYR61) in Graves' orbitopathy (GO). METHODS: Sera from 52 GO patients, 23 Graves' disease (GD) patients, and 20 healthy controls, and orbital fat tissue samples from 12 of 52 GO patients and 8 control subjects were included for analysis. Concentrations of CYR61 were measured from sera with an enzyme-linked immunosorbent assay, and CYR61 mRNA expression levels were evaluated from orbital fat tissue with polymerase chain reaction...
May 26, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28540010/changes-in-choroidal-perfusion-after-orbital-decompression-surgery-for-graves-ophthalmopathy
#2
Narieman Nik, Amelia Fong, Marianna Derdzakyan, Chrysavgi Adamopoulou, Adam Sise, Aziz Khanifar, Reginald Sanders
PURPOSE: To assess choroidal perfusion before and after orbital decompression surgery in patients with Graves' ophthalmopathy. METHODS: In this interventional case series, surgical decompression for optic nerve compromise was performed on four eyes of three patients with Graves' disease. Complete ophthalmic examination including visual acuity, color vision, and intraocular pressure assessment were done pre- and postoperatively. High-speed indocyanine green angiography was performed prior to surgery and was repeated one year after surgery...
April 2017: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/28492873/sphingosine-1-phosphate-mediates-fibrosis-in-orbital-fibroblasts-in-graves-orbitopathy
#3
JaeSang Ko, Min Kyoung Chae, Joon H Lee, Eun Jig Lee, Jin Sook Yoon
Purpose: To investigate the effect of sphingosine-1-phosphate (S1P) on fibrosis in orbital fibroblasts in Graves' orbitopathy (GO). Methods: Orbital fibroblasts were cultured from orbital adipose/connective tissues of patients with GO and healthy control subjects. Effects of treatment with TGF-β and cigarette smoke extract (CSE) on S1P receptor (S1PR) messenger RNA (mRNA) and S1P expression were evaluated by real-time polymerase chain reaction and Western blotting...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28457289/changes-in-pupillary-distance-after-fat-versus-bony-orbital-decompression-in-graves-orbitopathy
#4
Young Jun Woo, Jin Sook Yoon
OBJECTIVE: To report changes in pupillary distance (PD) after orbital decompression in patients with Graves' orbitopathy (GO). DESIGN: Retrospective comparative case series. PARTICIPANTS: A total of 59 cases who underwent the same type of orbital decompression on both eyes. METHODS: The medical records of 111 patients who underwent orbital decompression were reviewed retrospectively. Fifty-nine patients without restrictive myopathy who underwent the same procedure on both eyes were included...
April 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28450378/long-term-outcomes-of-orbital-fat-decompression-in-graves-orbitopathy
#5
Anny M Cheng, Yi-Hsuan Wei, Sean Tighe, Hosam Sheha, Shu-Lang Liao
PURPOSE: To evaluate the long-term clinical efficacy of orbital fat decompression in treating proptosis in Graves' ophthalmopathy (GO). METHODS: Retrospective review of 1604 eyes of 845 patients with symmetric (1518 eyes) and asymmetric (86 eyes) proptosis who received orbital fat decompression between 2003 and 2014. Changes in Hertel values were evaluated at baseline, 6 months postoperatively and yearly thereafter. Recurrence of proptosis, diplopia and other complications that required additional surgeries were documented and analysed...
April 27, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28439882/prevalence-and-clinical-relevance-of-tsh-receptor-blocking-antibodies-in-autoimmune-thyroid-disease
#6
T Diana, J Krause, P D Olivo, J König, M Kanitz, B Decallonne, G J Kahaly
OBJECTIVE: The prevalence and clinical relevance of TSH-receptor (TSHR) blocking antibodies (TBAb) in patients with autoimmune thyroid disease (AITD) was investigated. METHODS: Serum TBAb were measured with a reporter gene bioassay using chinese hamster ovary cells. Blocking activity was defined as percentage inhibition of luciferase expression relative to induction with bovine TSH alone (cut-off 40% inhibition). All samples were measured for TSHR stimulatory Ab (TSAb) and TSHR binding inhibiting immunoglobulins (TBII)...
April 25, 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/28427469/graves-orbitopathy-as-a-rare-disease-in-europe-a-european-group-on-graves-orbitopathy-eugogo-position-statement
#7
P Perros, L Hegedüs, L Bartalena, C Marcocci, G J Kahaly, L Baldeschi, M Salvi, J H Lazarus, A Eckstein, S Pitz, K Boboridis, P Anagnostis, G Ayvaz, A Boschi, T H Brix, N Currò, O Konuk, M Marinò, A L Mitchell, B Stankovic, F B Törüner, G von Arx, M Zarković, W M Wiersinga
BACKGROUND: Graves' orbitopathy (GO) is an autoimmune condition, which is associated with poor clinical outcomes including impaired quality of life and socio-economic status. Current evidence suggests that the incidence of GO in Europe may be declining, however data on the prevalence of this disease are sparse. Several clinical variants of GO exist, including euthyroid GO, recently listed as a rare disease in Europe (ORPHA466682). The objective was to estimate the prevalence of GO and its clinical variants in Europe, based on available literature, and to consider whether they may potentially qualify as rare...
April 20, 2017: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/28419103/establishment-of-a-tear-protein-biomarker-panel-differentiating-between-graves-disease-with-or-without-orbitopathy
#8
Cecilie Aass, Ingrid Norheim, Erik Fink Eriksen, Ellen Charlotte Børnick, Per Medbøe Thorsby, Milaim Pepaj
BACKGROUND: Graves' orbitopathy (GO) is an autoimmune inflammatory ocular complication and one of the most frequent manifestations of Graves' disease (GD). Clinical judgment of GO is subjective sometimes leading to clinical and therapeutic challenges. Better tools to diagnose this severe complication are warranted. PATIENTS AND METHODS: The aim of the present study was to evaluate tear levels of LYZ, LACRT and AZGP1 in GD patients with or without GO, as possible biomarkers for GO...
2017: PloS One
https://www.readbyqxmd.com/read/28379055/performance-of-apparent-diffusion-coefficient-of-medial-and-lateral-rectus-muscles-in-graves-orbitopathy
#9
Ahmed Ak Abdel Razek, Mohamed El-Hadidy, Mohamed E Moawad, Nader El-Metwaly, Amr A El-Said
Objective The purpose of this study was to determine the performance of the apparent diffusion coefficient in the detection of involvement of the medial and lateral rectus muscles in patients with Graves' orbitopathy. Methods and materials This prospective study was conducted on 33 consecutive patients (16 males, 17 females with a mean age of 36 years) with Graves' orbitopathy and 18 age- and sex-matched volunteers. The patients and volunteers underwent diffusion-weighted magnetic resonance imaging of the orbit in the axial plane using echo-planar imaging...
January 1, 2017: Neuroradiology Journal
https://www.readbyqxmd.com/read/28368444/cyclic-peptides-for-effective-treatment-in-a-long-term-model-of-graves%C3%A2-disease-and-orbitopathy-in-female-mice
#10
Hans-Peter Holthoff, Zhongmin Li, Julia Faßbender, Andreas Reimann, Kristin Adler, Götz Münch, Martin Ungerer
A model for human Graves´ disease in mice was used to compare several novel treatment approaches. The mice received regular adenoviral (Ad) thyroid-stimulating receptor (TSHR) A subunit immunisations (4-weekly injections). Generation of anti-TSHR antibodies, enlarged thyroid sizes (goiter), elevated serum thyroxin levels, retro-orbital fibrosis and cardiac involvement (tachycardia and hypertrophy) were consistently observed during 9 months.Treatment of established disease in these mice with novel cyclic peptides which mimic one of the cylindrical loops of the TSHR leucin-rich repeat domain improved or even cured all investigated parameters after 6 consecutive monthly injections...
March 29, 2017: Endocrinology
https://www.readbyqxmd.com/read/28364200/sphingosine-1-phosphate-is-involved-in-inflammatory-reactions-in-patients-with-graves-orbitopathy
#11
Yuri Seo, Min Kyung Chae, Sol Ah Han, Eun Jig Lee, Joon H Lee, Jin Sook Yoon
OBJECTIVE: Graves' orbitopathy (GO) is initiated by excessive amount of various inflammatory mediators produced by orbital fibroblasts. This study aimed to assess the crucial role of sphingosine-1-phosphate (S1P) in the inflammatory process of GO. METHODS: Orbital adipose/connective tissue samples were obtained from 10 GO patients and 10 normal control individuals during surgery. Primary orbital fibroblast culture was done. After the expression of S1P receptors and sphingosine kinase (SphK) was assessed with the treatment of interleukin (IL)-1β, we evaluated the expression of pro-inflammatory factors [intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase-2 (COX-2) and IL-6] after treating S1P...
March 31, 2017: Inflammation Research: Official Journal of the European Histamine Research Society ... [et Al.]
https://www.readbyqxmd.com/read/28258132/mortality-in-graves-orbitopathy-is-increased-and-influenced-by-gender-age-and-pre-existing-morbidity-a-nationwide-danish-register-study
#12
Charlotte F Schwensen, Frans Brandt, Laszlo Hegedüs, Thomas H Brix
INTRODUCTION: It is unclear whether the excess mortality associated with Graves' disease differs between individuals with Graves' orbitopathy (GO) or without (GD). SUBJECTS AND METHODS: A nationwide, register-based cohort study in which all adult Danes diagnosed with GD (n = 28 461) and GO (n = 3965) between 1995 and 2012 were matched for age and gender with four control subjects. Median follow-up time was 7.9 years (range 0-17.5). Mortality risk in GO patients compared to the control population and compared to GD patients was calculated using Cox regression analyses, adjusting for pre-existing morbidity using the Charlson score...
June 2017: European Journal of Endocrinology
https://www.readbyqxmd.com/read/28255299/selenium-and-thyroid-disease-from-pathophysiology-to-treatment
#13
REVIEW
Mara Ventura, Miguel Melo, Francisco Carrilho
Introduction. Selenium is a micronutrient embedded in several proteins. In adults, the thyroid is the organ with the highest amount of selenium per gram of tissue. Selenium levels in the body depend on the characteristics of the population and its diet, geographic area, and soil composition. In the thyroid, selenium is required for the antioxidant function and for the metabolism of thyroid hormones. Methods. We performed a review of the literature on selenium's role in thyroid function using PubMed/MEDLINE...
2017: International Journal of Endocrinology
https://www.readbyqxmd.com/read/28243204/icariin-inhibits-ampk-dependent-autophagy-and-adipogenesis-in-adipocytes-in-vitro-and-in-a-model-of-graves-orbitopathy-in-vivo
#14
Hong Li, Yifei Yuan, Yali Zhang, Xia Zhang, Long Gao, Rongjuan Xu
Graves' orbitopathy (GO), an extrathyroidal manifestation of Graves' disease, is an inflammatory autoimmune disorder of the orbit that involves the differentiation of precursor cells into mature adipocytes and retro-orbital adipose tissue accumulation. Here, we examined the involvement of autophagy in adipogenesis and explored the effects of icariin, a flavonoid isolated from the genus Epimedium with a wide range of biological and pharmacological effects, on autophagy and adipogenesis in 3T3-L1 preadipocytes and in a mouse model of GO...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28222462/decreased-frequencies-of-peripheral-blood-cd4-cd25-cd127-foxp3-in-patients-with-graves-disease-and-graves-orbitopathy-enhancing-effect-of-insulin-growth-factor-1-on-treg-cells
#15
Przemyslaw Pawlowski, Kamil Grubczak, Jerzy Kostecki, Elzbieta Ilendo-Poskrobko, Marcin Moniuszko, Malgorzata Pawlowska, Robert Rejdak, Joanna Reszec, Janusz Mysliwiec
Graves' orbitopathy (GO) is characterized by orbital T cell infiltration. We evaluated the regulatory T (Treg) cell fractions induced with IGF-1 in Graves' disease (GD) with and without GO. Peripheral blood mononuclear cells (PBMCs) were obtained from 13 patients with GD without eye manifestations; 10 patients with active GO; and 12 patients with nodular goiter (NG). All the patients from GD, GO, and NG were subclinical hyperthyroid. We analyzed the expression of Treg cell markers (CD4, CD25, CD127(-), Foxp3) on T cells and their ability to respond to IGF-1 stimulation...
March 2017: Hormone and Metabolic Research, Hormon- und Stoffwechselforschung, Hormones et Métabolisme
https://www.readbyqxmd.com/read/28182165/rituximab-treatment-in-a-patient-with-active-graves-orbitopathy-and-psoriasis
#16
Tülay Şimşek, Nilgün Yıldırım, Belgin Efe, Nur Kebapçı
Management of Graves' orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab suggests that it is a promising alternative therapy for Graves' orbitopathy. Here we report a case of a 49-year-old woman with Graves' orbitopathy and psoriasis. The patient received 2 infusions of 1 g rituximab 2 weeks apart...
January 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28181061/changing-trend-in-referral-to-secondary-care-specialist-thyroid-eye-disease-clinic-following-the-amsterdam-declaration
#17
Annika S Quinn, Leticia R Dujardin, Bridget Knight, James Benzimra, Anthony G Quinn, Bijay Vaidya
INTRODUCTION: Early diagnosis and treatment of thyroid eye disease (TED) improves outcomes. Previous studies have highlighted delays in diagnosis and referral to specialist centres. The Amsterdam declaration (2009) aimed to halve the time from presentation to diagnosis and from diagnosis to referral to a specialist centre in five years. A recent study from the European group on Graves' orbitopathy tertiary centres showed a trend for earlier referral of patients to the centres. It is unknown whether similar improvements are occurring in secondary care hospitals in the UK...
February 8, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28176220/does-early-response-to-intravenous-glucocorticoids-predict-the-final-outcome-in-patients-with-moderate-to-severe-and-active-graves-orbitopathy
#18
L Bartalena, G Veronesi, G E Krassas, W M Wiersinga, C Marcocci, M Marinò, M Salvi, C Daumerie, C Bournaud, M Stahl, L Sassi, C Azzolini, K G Boboridis, M P Mourits, M R Soeters, L Baldeschi, M Nardi, N Currò, A Boschi, M Bernard, G von Arx, P Perros, G J Kahaly
PURPOSE: Intravenous glucocorticoids (ivGCs) given as 12-weekly infusions are the first-line treatment for moderate-to-severe and active Graves' orbitopathy (GO), but they are not always effective. In this study, we evaluated whether response at 6 weeks correlated with outcomes at 12 (end of intervention) and 24 (follow-up) weeks, particularly in patients initially unresponsive. METHODS: Our database (Bartalena et al. J Clin Endocrinol Metab 97:4454-4463, 10), comprising 159 patients given three different cumulative doses of methylprednisolone (2...
February 7, 2017: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/28133945/objective-and-subjective-outcomes-of-strabismus-surgery-in-graves-orbitopathy-a-prospective-multicentre-study
#19
Hinke Marijke Jellema, Peerooz Saeed, Ilse Mombaerts, Peter J Dolman, Jim Garrity, Mike Kazim, Elona Dhrami-Gavazi, Christopher Lyons, Pythia Nieuwkerk, Maarten P Mourits
PURPOSE: To assess the change and interrelationship of the field of binocular single vision (BSV) and the quality of life (QoL), tested with two different tools, after one or two strabismus surgeries in patients with Graves' orbitopathy (GO). METHODS: Prospectively, consecutive patients with GO who were scheduled for their first strabismus surgery were recruited from five centres specialized in the treatment of GO. One week preoperatively and 3 months after the last operation, a full ophthalmic and orthoptic examination was performed...
January 30, 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28087387/orbital-fibroblasts-of-graves-orbitopathy-stimulated-with-proinflammatory-cytokines-promote-b-cell-survival-by-secreting-baff
#20
Fen Tang, Xiaoqing Chen, Yuxiang Mao, Shangtao Wan, Siming Ai, Huasheng Yang, Guangming Liu, Yusha Zou, Miaoli Lin, Liang Dan
The success of rituximab for the treatment of active Graves' orbitopathy (GO) suggests that B cells play a critical role in intraorbital inflammation. B cell activating factor (BAFF) and its homolog a proliferation-inducing ligand (APRIL) are critical for B cell survival. However, the contribution of BAFF/APRIL to GO remains unclear. We sought to determine the role of BAFF/APRIL in the orbits of GO, and found that BAFF was markedly upregulated, while APRIL was not. Additionally, cultured GO orbital fibroblasts (GO-OFs)(2) expressing BAFF were induced to produce a large amount of BAFF...
May 5, 2017: Molecular and Cellular Endocrinology
keyword
keyword
20691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"